Replies to post #192458 on Biotech Values

[biocqr]

EXAS > competitive threat from blood based CRC detection by Applied Proteomics...backed by Vulcan Capital/Paul Allen (Microsoft)...


Founded in 2007, Applied Proteomics Inc. (API) is advancing the application of proteomics for the development of diagnostics, companion diagnostics, and personalized medicine applications to power better medical decisions and care. API has developed a proprietary, industry-leading proteomics platform solution to make protein-based biomarker discovery possible as a replicable, cost efficient, and highly precise industrial application that is being applied to health diagnostic problems. API's first commercial product is a blood-based screening test for colorectal cancer to help risk stratify patients and drive colonoscopy compliance. In addition to advancing other diagnostic development programs in its pipeline, API remains focused on innovation and disruption within the diagnostics space. API is a privately-held Company headquartered in San Diego, CA.

http://www.appliedproteomics.com/